- Asahi Kasei receives Okochi Memorial Prize for its contribution to the pharmaceutical industry with MCC Ceolus™ UF grade.
- MCC Ceolus™ enhances tablet compactibility, flowability, and reduces nitrosamine risks with low nitrite levels.
- Asahi Kasei continues to innovate in the healthcare sector, supporting sustainable and efficient pharmaceutical production.
On April 25, Asahi Kasei, a leading Japanese technology company, was honored with the prestigious Okochi Memorial Prize. The award recognizes significant advancements in production engineering and technology research and development within Japan. The accolade highlights the company's development of the Microcrystalline Cellulose (MCC) Ceolus™ UF grade, which addresses key formulation issues in tablet manufacturing, such as poor compactibility and flowability.
The MCC Ceolus™ UF grade, developed under the leadership of Hideki Amakawa, sports a unique porous particle shape. This innovation ensures high compactibility and flowability, which are critical for tablet production. These improvements enhance tablet hardness and prevent manufacturing defects like capping and chipping. Furthermore, the product achieves high active pharmaceutical ingredient (API) uniformity, even in low-dose tablets, facilitating the development of challenging dosage forms such as small and easy-to-administer tablets.
In a bid to address health concerns, Asahi Kasei has also focused on reducing nitrosamine risks. The company provides MCC products with nitrite concentrations of 0.1 µg/g (ppm) or less, significantly below industry norms. This initiative follows the 2018 revelation of potentially carcinogenic nitrosamine impurities in certain pharmaceuticals, prompting widespread safety assessments guided by major regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA).
Asahi Kasei (AHKSY, Financial), with a market cap of $9.88 billion, continues its legacy of innovation by contributing to a sustainable society, aiming for carbon neutrality by 2050. The company operates across its three business sectors: Material, Homes, and Healthcare, serving numerous global markets and providing solutions to contemporary challenges.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
